A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administratio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yukinobu Watanabe MD, PhD, Masahiro Ogawa MD, PhD, Yu Tamura MD, Seiichiro Suda MD, Masahiro Kaneko MD, Mariko Kumagawa MD, Midori Hirayama MD, Naoki Matsumoto MD, PhD, Toshiki Yamamoto MD, PhD, Mitsuhiko Moriyama MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920 Pathology RB1-214
Acceso en línea:	https://doaj.org/article/783b9584d7a640a6921799fd32804d6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:783b9584d7a640a6921799fd32804d6c
record_format	dspace
spelling	oai:doaj.org-article:783b9584d7a640a6921799fd32804d6c2021-12-01T02:03:23ZA Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab2324-709610.1177/23247096211058489https://doaj.org/article/783b9584d7a640a6921799fd32804d6c2021-11-01T00:00:00Zhttps://doi.org/10.1177/23247096211058489https://doaj.org/toc/2324-7096A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.Yukinobu Watanabe MD, PhDMasahiro Ogawa MD, PhDYu Tamura MDSeiichiro Suda MDMasahiro Kaneko MDMariko Kumagawa MDMidori Hirayama MDNaoki Matsumoto MD, PhDToshiki Yamamoto MD, PhDMitsuhiko Moriyama MD, PhDSAGE PublishingarticleMedicine (General)R5-920PathologyRB1-214ENJournal of Investigative Medicine High Impact Case Reports, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920 Pathology RB1-214
spellingShingle	Medicine (General) R5-920 Pathology RB1-214 Yukinobu Watanabe MD, PhD Masahiro Ogawa MD, PhD Yu Tamura MD Seiichiro Suda MD Masahiro Kaneko MD Mariko Kumagawa MD Midori Hirayama MD Naoki Matsumoto MD, PhD Toshiki Yamamoto MD, PhD Mitsuhiko Moriyama MD, PhD A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
description	A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
format	article
author	Yukinobu Watanabe MD, PhD Masahiro Ogawa MD, PhD Yu Tamura MD Seiichiro Suda MD Masahiro Kaneko MD Mariko Kumagawa MD Midori Hirayama MD Naoki Matsumoto MD, PhD Toshiki Yamamoto MD, PhD Mitsuhiko Moriyama MD, PhD
author_facet	Yukinobu Watanabe MD, PhD Masahiro Ogawa MD, PhD Yu Tamura MD Seiichiro Suda MD Masahiro Kaneko MD Mariko Kumagawa MD Midori Hirayama MD Naoki Matsumoto MD, PhD Toshiki Yamamoto MD, PhD Mitsuhiko Moriyama MD, PhD
author_sort	Yukinobu Watanabe MD, PhD
title	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
title_short	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
title_full	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
title_fullStr	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
title_full_unstemmed	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
title_sort	case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/783b9584d7a640a6921799fd32804d6c
work_keys_str_mv	AT yukinobuwatanabemdphd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT masahiroogawamdphd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT yutamuramd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT seiichirosudamd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT masahirokanekomd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT marikokumagawamd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT midorihirayamamd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT naokimatsumotomdphd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT toshikiyamamotomdphd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT mitsuhikomoriyamamdphd acaseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT yukinobuwatanabemdphd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT masahiroogawamdphd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT yutamuramd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT seiichirosudamd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT masahirokanekomd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT marikokumagawamd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT midorihirayamamd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT naokimatsumotomdphd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT toshikiyamamotomdphd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab AT mitsuhikomoriyamamdphd caseofpseudoprogressioninhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumab
_version_	1718405969998774272

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Ejemplares similares